Viewing Study NCT05354635



Ignite Creation Date: 2024-05-06 @ 5:34 PM
Last Modification Date: 2024-10-26 @ 2:31 PM
Study NCT ID: NCT05354635
Status: NOT_YET_RECRUITING
Last Update Posted: 2022-04-29
First Post: 2022-04-26

Brief Title: Therapeutic Follow-up of Antibiotics in Pediatric Intensive Care
Sponsor: Centre Hospitalier Universitaire de la Réunion
Organization: Centre Hospitalier Universitaire de la Réunion

Study Overview

Official Title: Therapeutic Follow-up of Antibiotics in Pediatric Intensive Care
Status: NOT_YET_RECRUITING
Status Verified Date: 2022-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: STAR-P
Brief Summary: Currently recommendations for antibiotic testing ATS in adult intensive care have been published The 2018 SFAR and the Abdul- Aziz et al expert conference recommend routine testing for β-lactams aminoglycosides linezolid and vancomycin and provide plasma concentration goals No recommendations have been made for the pediatric intensive care unit PICU population However several articles report suboptimal plasma concentrations for the most frequently used antibiotics in PICU The University Hospital of Reunion is the reference center for the western region of the Indian Ocean This region presents a large mixed population due to the migratory flow as well as a specific bacterial ecology This suggests that the data already collected on antibiotic dosage in other European studies may not be fully extrapolated to Reunion Island

It is in this context that we will study the plasma concentration of antibiotics for all children who received the most commonly used antibiotics β-lactams linezolid vancomycin and aminoglycosides during their hospitalization in PICU
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None